Neonatal and pediatric focused drug information
Micromedex NeoFax and Pediatrics
Trusted guidance for treating your youngest patients
highlights
Micromedex NeoFax and Pediatric drug information
Building on the history and reputation of NeoFax, Micromedex neonatal and pediatrics content provides clinicians with trusted, evidence-based drug information for neonatal and pediatric patient care. The information is based on the same comprehensive editorial process behind Micromedex solutions, ensuring healthcare providers can rely on accurate data, guided by published literature, clinical guidelines, and regulatory information.
Ensure focus and save time
Workflow efficiency for clincians:
- Separate neonatal and pediatric monographs get you to the relevant population-specific information faster
- Easy comparison of multiple products including infant formulas and human milk fortifiers to help you tailor enteral nutrition support to meet the needs of each patient
Support patient safety
Accurate clinical decision support:
- Population-specific dosing based on indication and patient age, to help reduce errors for your smallest patients
- Information that provides context, relevance, and caveats around available supporting evidence to inform off-label treatment decisions
- The NeoFax and Pediatrics dosing calculators provide greater clinical accuracy and reliability in drug dosing
Access anywhere
Drug reference content where and when you need it:
- Full drug monograph and infant formula content is available online and on the new, consolidated mobile app
NEOFAX IN ACTION
Neonatal drug therapy differs significantly...
Managing drug therapy of cefTRIAXone for a premature neonatal baby in the neonatal intensive care unit (NICU) is not the same as managing a six year old child in the pediatric intensive care unit (PICU).
PEDIATRICS IN ACTION
...from pediatric drug therapy
There are clinically significant differences in all aspects of drug therapy for neonatal and pediatric populations: dose, uses, administration, monitoring, adverse effects and more. Providing distinct, focused drug information for these vulnerable populations is imperative so that clinicians have a clear point of reference for their specific patient.
